This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (540)

Published on in Vol 3, No 4 (2014): Oct-Dec

A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale

A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale

A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale

Authors of this article:

Attyla Drabik1 Author Orcid Image ;   Carina Hillgruber2 Author Orcid Image ;   Tobias Goerge2 Author Orcid Image
Article Authors Cited by (12) Tweetations (1) Metrics

Journals

  1. Renner R, Dissemond J, Goerge T, Hoff N, Kröger K, Erfurt‐Berge C. Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis. Journal of the European Academy of Dermatology and Venereology 2017;31(11):1884 View
  2. Nakayama T, Mizutani K, Hanamura I, Kato H, Takami A, Takeshita K, Watanabe D. Livedoid vasculopathy and popliteal artery occlusion in a patient with protein S deficiency. The Journal of Dermatology 2017;44(2):198 View
  3. Evans J, Jensen J, Sami N. Successful treatment of livedoid vasculopathy with rivaroxaban. JAAD Case Reports 2015;1(6):340 View
  4. Jiménez-Gallo D, Villegas-Romero I, Rodríguez-Mateos M, Linares-Barrios M. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists. Actas Dermo-Sifiliográficas (English Edition) 2018;109(3):278 View
  5. Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider S, Gerss J, Eveslage M, Drabik A, Goerge T. Characteristics, risk factors and treatment reality in livedoid vasculopathy – a multicentre analysis. Journal of the European Academy of Dermatology and Venereology 2019;33(9):1784 View
  6. Franco Marques G, Criado P, Alves Batista Morita T, Cajas García M. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban. International Journal of Dermatology 2018;57(6):732 View
  7. Lee J, Kim I. Case series of recalcitrant livedoid vasculopathy treated with rivaroxaban. Clinical and Experimental Dermatology 2016;41(5):559 View
  8. Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider S, Gerss J, Eveslage M, Drabik A, Goerge T. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. The Lancet Haematology 2016;3(2):e72 View
  9. Jiménez-Gallo D, Villegas-Romero I, Rodríguez-Mateos M, Linares-Barrios M. Vasculopatía livedoide tratada con rivaroxabán. Potenciales usos de los nuevos anticoagulantes orales para el dermatólogo. Actas Dermo-Sifiliográficas 2018;109(3):278 View
  10. Bilgic A, Ozcobanoglu S, Bozca B, Alpsoy E. Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management. International Journal of Women's Dermatology 2021;7(5):588 View
  11. Burg M, Mitschang C, Goerge T, Schneider S. Livedoid vasculopathy – A diagnostic and therapeutic challenge. Frontiers in Medicine 2022;9 View
  12. Deng S, Liu Y, Huang J, Shi W. Rivaroxaban in the treatment of livedoid vasculopathy: A long-term retrospective study. JAAD International 2024;14:36 View